Anacor Pharmaceuticals Announces GSK Has Initiated Two Phase 2 Trials Of GSK '052 In Complicated Urinary Tract Infections And CIAI

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that GlaxoSmithKline (GSK) has initiated two separate Phase 2b trials of GSK 2251052, or GSK '052 (formerly referred to as AN3365), in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). GSK '052 is a novel boron-based, systemic antibiotic being developed for the treatment of infections caused by Gram-negative bacteria. GSK '052 specifically targets the bacterial enzyme leucyl-transfer RNA synthetase, or LeuRS, which is required for protein synthesis...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/ZNyY6q7ybPY/229443.php

health fitness